argenx Appoints Steve Krognes to Board of Directors
Amsterdam, the Netherlands
argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that during the extraordinary general meeting of shareholders held today at 12:00pm CET, Steve Krognes was appointed as non-executive director to its Board of Directors. He will also become the chairperson of the Audit and Compliance Committee.
“We welcome Steve to the Board and are confident that with his strong financial and compliance expertise and valuable industry knowledge, he is the right profile to support argenx on our innovative, entrepreneurial mission,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx. “I would also like to express my gratitude to Werner for his substantial contributions over the last eight years. His entrepreneurial spirit combined with his broad experience in finance and executive leadership within biopharma has helped guide us from a research and development company to a fully integrated, global immunology company.”
As a result of the appointment of Mr. Krognes, Werner Lanthaler has formally resigned as non- executive director of the Board of Directors and chairperson of the Audit and Compliance Committee to enable this important step in long-term succession planning.
The voting result and all documents relating to the shareholders’ meeting will be available on the argenx website at www.argenx.com/investors/shareholder-meetings.
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first-and- only approved neonatal Fc receptor (FcRn) blocker in the U.S., the EU and Japan. For more information, visit www.argenx.com and follow us on LinkedIn, Twitter, and Instagram.
For further information, please contact: